Brendan Bioanalytics
Brendan Bioanalytics, formerly Brendan Technologies, is a specialized software developer focused on advanced analytical tools for bioassay data.
Profile
Develops software for analyzing bioassay data in pharmaceutical and clinical research labs.
Brendan Bioanalytics, formerly Brendan Technologies, is a specialized software developer focused on advanced analytical tools for bioassay data. The company rebranded in 2020 to better reflect its core focus on bioanalytical software, particularly for multiplex and singleplex immunoassays, potency bioassays, and immunogenicity assays. Its flagship product, STATLIA MATRIX, is designed to provide laboratories with robust data analysis, workflow management, and regulatory compliance features.
The software incorporates gold-standard statistical models like 5PL and 4PL curve fitting, automated weighting computations, and Monte Carlo methods for confidence interval estimation. Brendan Bioanalytics targets pharmaceutical, biotechnology, and clinical research laboratories seeking to standardize and optimize assay processes. While the company does not disclose revenue or headcount publicly, its software is positioned as an enterprise solution with support for multi-user environments, including LAN, cloud, and Citrix deployments.
The 2026 launch of STATLIA MATRIX MP expanded its capabilities for multiplex assay analysis, emphasizing detailed analyte-specific metrics and customizable reporting. The company maintains a support structure for both its legacy STATLIA 3.2 platform and the newer STATLIA MATRIX, though new sales are focused on the latter.
Products by Brendan Bioanalytics
- S STATLIA MATRIX STATLIA MATRIX is an enterprise bioanalytical software platform designed for regulated biopharmaceutical laboratories performing ELISA, relative potency, and Be the first to review →
- S STATLIA MATRIX MP STATLIA MATRIX MP is advanced analysis and workflow software designed for regulated biopharmaceutical laboratories running multiplex and singleplex Be the first to review →
Who buys this
- Pharmaceutical companies running immunoassays
- Biotechnology firms developing potency assays
- Clinical research organizations (CROs)
- Academic research labs studying immunogenicity
- Diagnostic labs performing ELISA/LBA testing
Strengths and what to watch
Strengths
- STATLIA MATRIX integrates advanced statistical models (5PL/4PL) with enterprise workflow management
- Legacy expertise in bioassay analytics, with peer-reviewed methodologies cited in literature
- Multi-platform support for LAN, cloud, and virtualized environments
Watch for
- Transition from legacy STATLIA 3.2 may create support challenges for existing customers
- No disclosed major pharmaceutical partnerships in public filings
- Intense competition from larger LIMS and bioanalytical software providers
Key Information
- Founded
- 2006
- Headquarters
- San Diego
Frequently Asked Questions
What does Brendan Bioanalytics do?
Brendan Bioanalytics develops specialized software for analyzing bioassay data in pharmaceutical and clinical research labs. Their flagship product, STATLIA MATRIX, provides advanced analytical tools for immunoassays, potency bioassays, and immunogenicity testing, with features for workflow management and regulatory compliance. The company rebranded in 2020 to focus on bioanalytical solutions.
What types of labs use STATLIA MATRIX software?
STATLIA MATRIX serves pharmaceutical companies running immunoassays, biotech firms developing potency assays, clinical research organizations, academic immunogenicity labs, and diagnostic facilities performing ELISA/LBA testing. The software is designed for enterprises needing standardized assay processes across multi-user environments, including cloud, LAN, and virtualized deployments.
What statistical methods does STATLIA MATRIX include?
The software incorporates gold-standard statistical models like 5PL and 4PL curve fitting for bioassay analysis. It features automated weighting computations and Monte Carlo methods for confidence interval estimation. These advanced algorithms help labs achieve precise, reproducible results for multiplex and singleplex immunoassays while maintaining regulatory compliance.
How does STATLIA MATRIX handle multiplex assay analysis?
The 2026 STATLIA MATRIX MP update expanded multiplex assay capabilities, offering detailed analyte-specific metrics and customizable reporting. The software processes complex multiplex data while maintaining the same rigorous statistical standards as its singleplex analysis, including 5PL curve fitting and automated quality control features for enterprise-scale research environments.
Can STATLIA MATRIX integrate with existing lab systems?
Yes, STATLIA MATRIX supports integration across multiple deployment environments including LAN, cloud, and Citrix virtualized setups. The enterprise solution is designed for multi-user access with workflow management features that can interface with existing laboratory information systems while maintaining data security and compliance standards.
Is Brendan Bioanalytics still supporting older STATLIA versions?
While focusing new sales on STATLIA MATRIX, Brendan Bioanalytics maintains support for legacy STATLIA 3.2 users. The company offers a structured transition path for customers upgrading to the newer platform, which includes enhanced statistical models, multiplex analysis capabilities, and modernized deployment options compared to the older version.
Sources
- www.brendan.com — Company rebranding and product positioning
- www.brendan.com — Product support structure and version status
- www.brendan.com — Core product offerings and capabilities
- investor.iconplc.com — Industry context (though no direct relationship with ICON plc)